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More than 350 million people worldwide are chronically
infected with HBV. The prevalence is particularly high
in South East Asia, Sub-Saharan Africa and South
America. In developed regions, the rate of chronic hepa-
titis B is declining mainly as result of universal HBV
vaccine programs, although immigration from HBV
endemic areas represents a continuous source of
incident cases.
Viral load and HBV genotype influences the natural
history of chronic hepatitis B and progression of liver
fibrosis. Treatment must be considered for individuals
with serum HBV-DNA above 2000 IU/ml, given their
increased risk of cirrhosis and liver cancer. Non-invasive
tools for assessing liver fibrosis, such as elastometry
(FibroScan) are rapidly replacing liver biopsy to guide
treatment decisions.
Besides peginterferon, five nucleos(t)ide analogues
(lamivudine, adefovir, telbivudine, entecavir and tenofo-
vir) have been approved for the treatment of chronic
hepatitis B; it is unlikely that any more will be available
in the near future. Cross-resistance is common between
all these drugs, although in different extent. Therefore,
an adequate design of effective therapeutic strategies is
crucial for long-term benefit using these drugs. Patients
that experience virologic breakthrough or partial
response to their primary therapy can often be success-
fully treated with a second nucleos(t)ide analogue, pre-
ferentially when the rescue intervention is done at early
stages of failure. However, best strategies for preventing
drug resistance include first-line use of the most potent
antivirals with a high barrier to resistance (namely teno-
fovir or entecavir) and/or combination therapy. At this
time, the use of lamivudine or adefovir as single agents
in first-line therapy is no longer recommended, given
their low-genetic barrier to resistance and weak activity,
respectively.
The genes that encode the polymerase and envelope
proteins of HBV overlap, so resistance mutations in
polymerase usually affect the hepatitis B surface anti-
gen; these alterations affect infectivity, vaccine efficacy,
pathogenesis of liver disease, and transmission
throughout the population. Primary lamivudine resis-
tance-associated mutations in HBV are now being seen
in 10% of new HBV infections in Western Europe and
North America.
A particular considerations merit the coinfection with
HIV or the superinfection by delta virus. Specific guide-
lines for managing HBV in HIV+ individuals have been
released (AIDS 2008, 22:1399–1410). The fixed combi-
nation of tenofovir plus emtricitabine (Truvada) is the
preferred option in most HIV-HBV coinfected patients.
The role of entecavir or telbivudine in this setting is
hampered by the recognition of low anti-HIV activity
and possibility of selecting resistance mutations in HIV.
With respect to hepatitis delta, preliminary data suggest
that potent nucleotide analogues as tenofovir may exert
some benefit in a subset of individuals with chronic
hepatitis delta, although data are too preliminary.
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